Skip to content
Sign in
Artwork for The Readout Loud
The Readout Loud · June 25 · 42 min

407: The mysterious case of Eli Lilly's obesity drug

Who got exclusive access to Eli Lilly's highly anticipated obesity candidate? Why are drugmakers spending so much money on acquisitions? And are hair loss drugs a good investment? We discuss all that and more on this week's episode of “The Readout LOUD,” STAT's biotech podcast. We bring on our colleague Lizzy Lawrence to discuss her scoop that Lilly and the Food and Drug Administration have allowed one person to receive the pharma company's obesity candidate, retatrutide, through the FDA’s “compassionate use” program. We also discuss the resurgence of M&A, Lilly's interest in a hair loss drug, and then the FDA's reversal on rare disease drugs.

0:00-42:45
Play in podnod

transcript

No transcript — this publisher did not publish one.

show notes

Who got exclusive access to Eli Lilly's highly anticipated obesity candidate? Why are drugmakers spending so much money on acquisitions? And are hair loss drugs a good investment?


We discuss all that and more on this week's episode of “The Readout LOUD,” STAT's biotech podcast. We bring on our colleague Lizzy Lawrence to discuss her scoop that Lilly and the Food and Drug Administration have allowed one person to receive the pharma company's obesity candidate, retatrutide, through the FDA’s “compassionate use” program.


We also discuss the resurgence of M&A, Lilly's interest in a hair loss drug, and then the FDA's reversal on rare disease drugs.

more episodes

All episodes